Voriconazole

• 

  Subject Areas on Research

  • Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species. 
  • Antifungal resistance: the clinical front. 
  • Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. 
  • Blastomycosis. 
  • Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. 
  • Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. 
  • Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. 
  • Case 215: voriconazole-induced periostitis. 
  • Caspofungin for the treatment of azole resistant candidemia in a premature infant. 
  • Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. 
  • Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. 
  • Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. 
  • Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. 
  • Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. 
  • Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. 
  • Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. 
  • Delayed recalcitrant fungal endophthalmitis secondary to Curvularia. 
  • Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation. 
  • Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in India. 
  • Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients. 
  • Improved outcome in central nervous system aspergillosis, using voriconazole treatment. 
  • In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. 
  • In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. 
  • Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. 
  • Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. 
  • Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia. 
  • Invasive Curvularia Infection in Pediatric Patients With Hematologic Malignancy Identified by Fungal Sequencing. 
  • Old and new: appropriate dosing for neonatal antifungal drugs in the nursery. 
  • Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. 
  • Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. 
  • Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis. 
  • Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. 
  • Real-world implications of QT prolongation in patients receiving voriconazole and amiodarone. 
  • Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia. 
  • Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. 
  • Scanning Quadrupole Data-Independent Acquisition, Part B: Application to the Analysis of the Calcineurin-Interacting Proteins during Treatment of Aspergillus fumigatus with Azole and Echinocandin Antifungal Drugs. 
  • Scedosporium prolificans osteomyelitis in an immunocompetent child treated with voriconazole and caspofungin, as well as locally applied polyhexamethylene biguanide. 
  • Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. 
  • Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children. 
  • Use of newer antifungal therapies in clinical practice: what do the data tell us? 
  • Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data. 
  • Voriconazole Treatment for an Infant With Intractable Candida glabrata Meningitis. 
  • Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. 
  • Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. 
  • Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. 
  • Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008-2019. 
  • Voriconazole treatment for less-common, emerging, or refractory fungal infections.